Merck & Co., Inc. (NYSE:MRK) Shares Sold by Private Advisor Group LLC

Private Advisor Group LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 25.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 347,805 shares of the company’s stock after selling 118,699 shares during the quarter. Private Advisor Group LLC’s holdings in Merck & Co., Inc. were worth $26,656,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in MRK. Financial Avengers Inc. increased its stake in shares of Merck & Co., Inc. by 115.8% in the fourth quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock worth $25,000 after acquiring an additional 176 shares during the period. Moisand Fitzgerald Tamayo LLC grew its position in Merck & Co., Inc. by 78.0% during the fourth quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after buying an additional 156 shares during the period. Retirement Group LLC grew its position in Merck & Co., Inc. by 116.4% during the third quarter. Retirement Group LLC now owns 608 shares of the company’s stock valued at $30,000 after buying an additional 327 shares during the period. Bellwether Advisors LLC grew its position in Merck & Co., Inc. by 460.0% during the third quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock valued at $31,000 after buying an additional 345 shares during the period. Finally, Steward Financial Group LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 72.88% of the company’s stock.

Shares of NYSE:MRK traded up $0.80 during midday trading on Tuesday, hitting $93.12. The company’s stock had a trading volume of 194,329 shares, compared to its average volume of 11,364,058. The business’s 50 day simple moving average is $84.27 and its 200 day simple moving average is $80.68. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.27. The company has a market cap of $235.48 billion, a P/E ratio of 16.52, a price-to-earnings-growth ratio of 1.22 and a beta of 0.37. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $92.87.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.31. The firm had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The company’s revenue for the quarter was up 31.6% on a year-over-year basis. During the same period last year, the firm posted $1.40 earnings per share. On average, sell-side analysts predict that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

MRK has been the topic of several analyst reports. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. SVB Leerink dropped their price target on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Barclays raised their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. StockNews.com initiated coverage on shares of Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Finally, JPMorgan Chase & Co. dropped their target price on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, January 28th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $90.69.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.